Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine

References

• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291 - 5; http://dx.doi.org/10.1126/science.1183021; PMID: 20075244
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805 - 20; http://dx.doi.org/10.1016/j.cell.2010.01.022; PMID: 20303872
   PubMed Web of Science ®Google Scholar
• Drane DCG, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6:761 - 72; http://dx.doi.org/10.1586/14760584.6.5.761; PMID: 17931156
   PubMed Web of Science ®Google Scholar
• Sjölander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Deliv Rev 1998; 34:321 - 38; http://dx.doi.org/10.1016/S0169-409X(98)00046-5; PMID: 10837684
   PubMed Web of Science ®Google Scholar
• Sjölander A, Drane D, Maraskovsky E, Scheerlinck JP, Suhrbier A, Tennent J, Pearse M. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001; 19:2661 - 5; http://dx.doi.org/10.1016/S0264-410X(00)00497-7; PMID: 11257406
   PubMed Web of Science ®Google Scholar
• Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, et al, NIAID AIDS Vaccine Evaluation Group. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001; 19:2080 - 91; http://dx.doi.org/10.1016/S0264-410X(00)00415-1; PMID: 11228380
   PubMed Web of Science ®Google Scholar
• Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, Anderson C, Kensil CR. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001; 19:3957 - 67; http://dx.doi.org/10.1016/S0264-410X(01)00142-6; PMID: 11427271
   PubMed Web of Science ®Google Scholar
• McKenzie A, Watt M, Gittleson C. ISCOMATRIX() vaccines: Safety in human clinical studies. Hum Vaccin 2010; 6:237 - 46; http://dx.doi.org/10.4161/hv.6.3.10754; PMID: 20595811
   PubMed Web of Science ®Google Scholar
• Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012; 61:935 - 43; http://dx.doi.org/10.1099/jmm.0.040857-0; PMID: 22442293
   PubMed Web of Science ®Google Scholar
• Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011; 187:55 - 63; http://dx.doi.org/10.4049/jimmunol.1004114; PMID: 21613613
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, Airey D, Provan L, Hass P, Braley H, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2012; 90:540 - 52; http://dx.doi.org/10.1038/icb.2011.71; PMID: 21894173
   PubMed Web of Science ®Google Scholar
• Pearse MJ, Drane D. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 2004; 22:2391 - 5; http://dx.doi.org/10.1016/j.vaccine.2003.12.031; PMID: 15193400
   PubMed Web of Science ®Google Scholar
• Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008; 82:6458 - 69; http://dx.doi.org/10.1128/JVI.00068-08; PMID: 18448544
   PubMed Web of Science ®Google Scholar
• Kennedy JS, Co M, Green S, Longtine K, Longtine J, O’Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008; 26:4420 - 4; http://dx.doi.org/10.1016/j.vaccine.2008.05.090; PMID: 18588934
   PubMed Web of Science ®Google Scholar
• Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005; 34:226 - 36; http://dx.doi.org/10.1111/j.1600-0684.2005.00120.x; PMID: 16128917
   PubMed Web of Science ®Google Scholar
• Buglione-Corbett R, Pouliot K, Marty-Roix R, West K, Wang S, Lien E, Lu S. Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One 2013; 8:e74820; http://dx.doi.org/10.1371/journal.pone.0074820; PMID: 24019983
   PubMed Web of Science ®Google Scholar
• Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108 - 25; http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005; PMID: 16051804
   PubMed Web of Science ®Google Scholar
• Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80:11776 - 90; http://dx.doi.org/10.1128/JVI.01730-06; PMID: 16971434
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947 - 57; http://dx.doi.org/10.1016/j.vaccine.2007.12.060; PMID: 18724414
   PubMed Web of Science ®Google Scholar
• Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011; 3:920 - 40; http://dx.doi.org/10.3390/v3060920; PMID: 21994762
   PubMed Web of Science ®Google Scholar
• de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al, Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188:5166 - 76; http://dx.doi.org/10.4049/jimmunol.1102756; PMID: 22529301
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al, MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209 - 20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID: 19843557
   PubMed Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005; 79:7933 - 7; http://dx.doi.org/10.1128/JVI.79.12.7933-7937.2005; PMID: 15919951
   PubMed Web of Science ®Google Scholar
• Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012; 61:935 - 43; http://dx.doi.org/10.1099/jmm.0.040857-0; PMID: 22442293
   PubMed Web of Science ®Google Scholar
• Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O’Hagan DT, Pétrilli V, Tschopp J, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009; 106:870 - 5; http://dx.doi.org/10.1073/pnas.0804897106; PMID: 19139407
   PubMed Web of Science ®Google Scholar
• Hayday AC, Peakman M. The habitual, diverse and surmountable obstacles to human immunology research. Nat Immunol 2008; 9:575 - 80; http://dx.doi.org/10.1038/ni0608-575; PMID: 18490903
   PubMed Web of Science ®Google Scholar
• Pal R, Yu Q, Wang S, Kalyanaraman VS, Nair BC, Hudacik L, Whitney S, Keen T, Hung CL, Hocker L, et al. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 2006; 24:1225 - 34; http://dx.doi.org/10.1016/j.vaccine.2005.07.112; PMID: 16219399
   PubMed Web of Science ®Google Scholar
• Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al, Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110:3507 - 12; http://dx.doi.org/10.1073/pnas.1222878110; PMID: 23401516
   PubMed Web of Science ®Google Scholar
• Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation and the Host Response to Injury Investigators. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005; 12:60 - 7; PMID: 15642986
   PubMedGoogle Scholar
• Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9:143 - 50; http://dx.doi.org/10.1016/S1074-7613(00)80596-8; PMID: 9697844
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010; 28:2999 - 3007; http://dx.doi.org/10.1016/j.vaccine.2010.02.006; PMID: 20170767
   PubMed Web of Science ®Google Scholar